# US 2010/0266624 A1 · Hepatitis-c virus testing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0266624 A1
- Document ID: US20100266624A1
- Status: Published application
- Kind: A1
- Application number: 12/728,030
- Filed: 2010-03-19
- Published: 2010-10-21
- Earliest claimed: 1991-11-21
- Assignees: Common Services Agency
- Inventors: Peter Simmonds; Shiu-Wan Chan; Peng Lee Yap
- Web page: https://patentgrep.com/patent/US20100266624A1

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- C12Q 1/707: {non-A, non-B Hepatitis, excluding hepatitis D}
- G01N 33/56983: {Viruses}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- G01N 2333/18: Togaviridae; Flaviviridae
- G01N 2333/186: Hepatitis C; Hepatitis NANB
- Y10S 436/82: Hepatitis associated antigens and antibodies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.

## Claims

### Claim 1

An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:15.

### Claim 2

An immunoassay device that comprises a solid substrate having attached thereto a polypeptide comprising the amino acid sequence of SEQ ID NO:15.

### Claim 3 (depends on 2)

A device according to claim 2 for HCV-typing, wherein said solid substrate comprises a series of locations respectively containing HCV-1, HCV-2, HCV-3, and HCV-4 specific antigens.

### Claim 4 (depends on 2)

A device according to claim 2, wherein at each location is provided a blocking amount of heterologous-type HCV oligopeptides to ensure that only antibody with type-specific antibody reactivity binds to the solid substrate.

### Claim 5

A fusion polypeptide comprising a first polypeptide operably linked to a heterologous protein or fragment, wherein said first polypeptide comprises the polypeptide set forth in SEQ ID NO:15.

### Claim 6 (depends on 5)

The fusion polypeptide of claim 5, wherein said heterologous fragment is β-galactosidase, GST, trp E, or a polyhedron coding sequence.

### Claim 7 (depends on 5)

A fusion polypeptide of claim 5, wherein said fusion polypeptide is labelled.

### Claim 8

A fusion polypeptide comprising at least two polypeptides wherein one polypeptide is SEQ ID NO:15, and wherein said at least two polypeptides are operably linked together.

### Claim 9

A vaccine formulation comprising at least one polypeptide wherein said polypeptide is SEQ ID NO:15.

### Claim 10

A composition comprising a polypeptide consisting of SEQ ID NO:15 and a pharmaceutically acceptable carrier.

### Claim 11

A method for detecting HCV infection in a mammal, comprising:
a) obtaining a blood sample from said mammal;
b) contacting said blood sample with at least one polypeptide consisting of SEQ ID NO:15; and,
c) detecting if an antibody present in said blood sample is bound to said polypeptide.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the composition is an immunoreactive composition.
